guest ::
| Home > Publications Database > Exploring the ATN classification system using brain morphology. > print |
| Home > Publications Database > Exploring the ATN classification system using brain morphology. > print |
| 001 | 256606 | ||
| 005 | 20240826165950.0 | ||
| 024 | 7 | _ | |a pmid:36915139 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC10009950 |2 pmc |
| 024 | 7 | _ | |a 10.1186/s13195-023-01185-x |2 doi |
| 024 | 7 | _ | |a altmetric:143970761 |2 altmetric |
| 037 | _ | _ | |a DZNE-2023-00358 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Heinzinger, Nils |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Exploring the ATN classification system using brain morphology. |
| 260 | _ | _ | |a London |c 2023 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1721636548_12034 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a CC BY |
| 520 | _ | _ | |a The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort.We used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups.The ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead.Using the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy.DRKS00007966, 04/05/2015, retrospectively registered. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to DataCite, PubMed, |
| 650 | _ | 7 | |a Alzheimer’s disease |2 Other |
| 650 | _ | 7 | |a ATN |2 Other |
| 650 | _ | 7 | |a Alzheimer’s disease |2 Other |
| 650 | _ | 7 | |a Amyloid |2 Other |
| 650 | _ | 7 | |a Biomarker |2 Other |
| 650 | _ | 7 | |a MRI |2 Other |
| 650 | _ | 7 | |a Memory |2 Other |
| 650 | _ | 7 | |a VBM |2 Other |
| 650 | _ | 7 | |a Voxel-based morphometry |2 Other |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Amyloidogenic Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Bayes Theorem |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Brain: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Amyloidogenic Proteins |2 MeSH |
| 650 | _ | 2 | |a tau Proteins |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 693 | _ | _ | |0 EXP:(DE-2719)DELCODE-20140101 |5 EXP:(DE-2719)DELCODE-20140101 |e Longitudinal Cognitive Impairment and Dementia Study |x 0 |
| 700 | 1 | _ | |a Maass, Anne |0 P:(DE-2719)2811815 |b 1 |u dzne |
| 700 | 1 | _ | |a Berron, David |0 P:(DE-2719)2812972 |b 2 |u dzne |
| 700 | 1 | _ | |a Yakupov, Renat |0 P:(DE-2719)2812398 |b 3 |u dzne |
| 700 | 1 | _ | |a Peters, Oliver |0 P:(DE-2719)2811024 |b 4 |u dzne |
| 700 | 1 | _ | |a Fiebach, Jochen |b 5 |
| 700 | 1 | _ | |a Villringer, Kersten |b 6 |
| 700 | 1 | _ | |a Preis, Lukas |0 P:(DE-2719)9000703 |b 7 |u dzne |
| 700 | 1 | _ | |a Priller, Josef |0 P:(DE-2719)2811122 |b 8 |u dzne |
| 700 | 1 | _ | |a Spruth, Eike Jacob |0 P:(DE-2719)2812446 |b 9 |u dzne |
| 700 | 1 | _ | |a Altenstein, Slawek |0 P:(DE-2719)2811720 |b 10 |u dzne |
| 700 | 1 | _ | |a Schneider, Anja |0 P:(DE-2719)2812035 |b 11 |u dzne |
| 700 | 1 | _ | |a Fliessbach, Klaus |0 P:(DE-2719)2811326 |b 12 |u dzne |
| 700 | 1 | _ | |a Wiltfang, Jens |0 P:(DE-2719)2811317 |b 13 |u dzne |
| 700 | 1 | _ | |a Bartels, Claudia |0 P:(DE-2719)9000444 |b 14 |u dzne |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 15 |u dzne |
| 700 | 1 | _ | |a Maier, Franziska |b 16 |
| 700 | 1 | _ | |a Glanz, Wenzel |0 P:(DE-2719)2811614 |b 17 |u dzne |
| 700 | 1 | _ | |a Buerger, Katharina |0 P:(DE-2719)2811351 |b 18 |u dzne |
| 700 | 1 | _ | |a Janowitz, Daniel |0 P:(DE-2719)9002557 |b 19 |u dzne |
| 700 | 1 | _ | |a Perneczky, Robert |0 P:(DE-2719)2812234 |b 20 |u dzne |
| 700 | 1 | _ | |a Rauchmann, Boris Stephan |0 P:(DE-2719)9001808 |b 21 |u dzne |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 22 |u dzne |
| 700 | 1 | _ | |a Killimann, Ingo |0 P:(DE-2719)2810394 |b 23 |u dzne |
| 700 | 1 | _ | |a Göerß, Doreen |b 24 |
| 700 | 1 | _ | |a Laske, Christoph |0 P:(DE-2719)2000055 |b 25 |u dzne |
| 700 | 1 | _ | |a Munk, Matthias H |0 P:(DE-2719)9001516 |b 26 |u dzne |
| 700 | 1 | _ | |a Spottke, Annika |0 P:(DE-2719)2811324 |b 27 |u dzne |
| 700 | 1 | _ | |a Roy, Nina |0 P:(DE-2719)2812341 |b 28 |u dzne |
| 700 | 1 | _ | |a Heneka, Michael T |0 P:(DE-2719)2000008 |b 29 |u dzne |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 30 |u dzne |
| 700 | 1 | _ | |a Dobisch, Laura |0 P:(DE-2719)2811611 |b 31 |u dzne |
| 700 | 1 | _ | |a Ewers, Michael |0 P:(DE-2719)9000543 |b 32 |u dzne |
| 700 | 1 | _ | |a Dechent, Peter |b 33 |
| 700 | 1 | _ | |a Haynes, John Dylan |b 34 |
| 700 | 1 | _ | |a Scheffler, Klaus |b 35 |
| 700 | 1 | _ | |a Wolfsgruber, Steffen |0 P:(DE-2719)2810544 |b 36 |u dzne |
| 700 | 1 | _ | |a Kleineidam, Luca |0 P:(DE-2719)2812139 |b 37 |u dzne |
| 700 | 1 | _ | |a Schmid, Matthias |0 P:(DE-2719)2811245 |b 38 |u dzne |
| 700 | 1 | _ | |a Berger, Moritz |b 39 |
| 700 | 1 | _ | |a Düzel, Emrah |0 P:(DE-2719)2000005 |b 40 |e Last author |u dzne |
| 700 | 1 | _ | |a Ziegler, Gabriel |0 P:(DE-2719)2814076 |b 41 |e Last author |u dzne |
| 700 | 1 | _ | |a Initiative, Alzheimer’s Disease Neuroimaging |b 42 |e Collaboration Author |
| 773 | _ | _ | |a 10.1186/s13195-023-01185-x |0 PERI:(DE-600)2506521-X |n 1 |p 50 |t Alzheimer's research & therapy |v 15 |y 2023 |x 1758-9193 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/256606/files/DZNE-2023-00358%20SUP.zip |
| 856 | 4 | _ | |u https://pub.dzne.de/record/256606/files/DZNE-2023-00358.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/256606/files/DZNE-2023-00358.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:256606 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2811815 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2812972 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2812398 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2811024 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-2719)9000703 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2811122 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812446 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2811720 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2812035 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811326 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2811317 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 14 |6 P:(DE-2719)9000444 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2000032 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)2811614 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2811351 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 19 |6 P:(DE-2719)9002557 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2812234 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 21 |6 P:(DE-2719)9001808 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2000026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)2810394 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)2000055 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)9001516 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 27 |6 P:(DE-2719)2811324 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 28 |6 P:(DE-2719)2812341 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 29 |6 P:(DE-2719)2000008 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 30 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 31 |6 P:(DE-2719)2811611 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 32 |6 P:(DE-2719)9000543 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 36 |6 P:(DE-2719)2810544 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 37 |6 P:(DE-2719)2812139 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 38 |6 P:(DE-2719)2811245 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 40 |6 P:(DE-2719)2000005 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 41 |6 P:(DE-2719)2814076 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 1 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-08 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-08 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-08 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-08 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS RES THER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T15:09:21Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T15:09:21Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2023-04-12T15:09:21Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ALZHEIMERS RES THER : 2022 |d 2023-08-19 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1311001 |k AG Maaß |l Multimodal Neuroimaging |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)5000070 |k AG Berron |l Clinical Cognitive Neuroscience |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1810002 |k AG Dirnagl |l Vascular Pathology |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)5000007 |k AG Priller |l Translational Neuropsychiatry |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 5 |
| 920 | 1 | _ | |0 I:(DE-2719)1011305 |k AG Schneider |l Translational Dementia Research (Bonn) |x 6 |
| 920 | 1 | _ | |0 I:(DE-2719)1011101 |k Patient Studies Bonn |l Patient Studies Bonn |x 7 |
| 920 | 1 | _ | |0 I:(DE-2719)1410006 |k AG Wiltfang |l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases |x 8 |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 9 |
| 920 | 1 | _ | |0 I:(DE-2719)5000022 |k AG Dichgans |l Vascular Cognitive Impairment & Post-Stroke Dementia |x 10 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 11 |
| 920 | 1 | _ | |0 I:(DE-2719)1011401 |k Clinical Research Platform (CRP) |l Clinical Research Platform (CRP) |x 12 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research (Rostock /Greifswald) |x 13 |
| 920 | 1 | _ | |0 I:(DE-2719)1011301 |k Biomarker |l Interventional Trials and Biomarkers in Neurodegenerative Diseases |x 14 |
| 920 | 1 | _ | |0 I:(DE-2719)1110008 |k AG Simons |l Molecular Neurobiology |x 15 |
| 920 | 1 | _ | |0 I:(DE-2719)1011201 |k AG Wagner |l Neuropsychology |x 16 |
| 920 | 1 | _ | |0 I:(DE-2719)1013028 |k AG Schmid Bonn |l Mathematics, statistics and informatics methods for support of population studies and clinical research |x 17 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | _ | _ | |a I:(DE-2719)1311001 |
| 980 | _ | _ | |a I:(DE-2719)5000070 |
| 980 | _ | _ | |a I:(DE-2719)1810002 |
| 980 | _ | _ | |a I:(DE-2719)5000007 |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | _ | _ | |a I:(DE-2719)1011305 |
| 980 | _ | _ | |a I:(DE-2719)1011101 |
| 980 | _ | _ | |a I:(DE-2719)1410006 |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | _ | _ | |a I:(DE-2719)5000022 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)1011401 |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | _ | _ | |a I:(DE-2719)1011301 |
| 980 | _ | _ | |a I:(DE-2719)1110008 |
| 980 | _ | _ | |a I:(DE-2719)1011201 |
| 980 | _ | _ | |a I:(DE-2719)1013028 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|